Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $181000.0.

  • Pulmonx's Cash from Financing Activities fell 6056.64% to $181000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $840000.0, marking a year-over-year decrease of 3626.71%. This contributed to the annual value of $1.4 million for FY2024, which is 9363.08% down from last year.
  • Latest data reveals that Pulmonx reported Cash from Financing Activities of $181000.0 as of Q3 2025, which was down 6056.64% from -$67000.0 recorded in Q2 2025.
  • In the past 5 years, Pulmonx's Cash from Financing Activities ranged from a high of $20.7 million in Q1 2023 and a low of -$67000.0 during Q2 2025
  • In the last 5 years, Pulmonx's Cash from Financing Activities had a median value of $181000.0 in 2025 and averaged $1.6 million.
  • In the last 5 years, Pulmonx's Cash from Financing Activities surged by 1001538.46% in 2022 and then crashed by 20454.55% in 2025.
  • Pulmonx's Cash from Financing Activities (Quarter) stood at $150000.0 in 2021, then tumbled by 55.33% to $67000.0 in 2022, then plummeted by 74.63% to $17000.0 in 2023, then soared by 264.71% to $62000.0 in 2024, then surged by 191.94% to $181000.0 in 2025.
  • Its Cash from Financing Activities stands at $181000.0 for Q3 2025, versus -$67000.0 for Q2 2025 and $664000.0 for Q1 2025.